Table 2 Public funding of ICR’s development work on olaparib
From: Counting the cost of public and philanthropic R&D funding: the case of olaparib
Funder’s Name | Funder’s Status | Number of grants | Total sum of grants (£) | Research awards in other currencies |
|---|---|---|---|---|
Cancer Research UK | Charity | 18 | £ 72,861,124.08 |  |
Breast Cancer Now | Charity | 6 | £ 130,173,644.00 |  |
National Institute for Health Research | National government | 4 | £ 194,492,365.00 |  |
Prostate Cancer UK | Charity | 3 | £ 6,874,700.88 |  |
Medical Research Council | National government | 2 | £ 484,306.12 |  |
Stand Up to Cancer | Charity | 2 | £ 10,667,84.00 | $10,000,000.00 |
European Commission | Supranational | 1 | £ 197,754.00 |  |
Prostate Cancer Foundation | Charity | 1 | Â | $225,000.00 |
National Health and Medical Research Council of Australia | National government | 1 | £ 841,075.00 |  |
Sum in original currency |  | 38 | £ 406,991,753.00 | $10,225,000.00 |
Total in common GBP £ currency ($ and €) |  |  | £ 414,414,081.00 ($ 570,896,929.00 or € 480,424,392.05) | |